Non-Hodgkin's Lymphoma, Phase III
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Volunteers
Health Professionals
What is the purpose of this trial?
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alexis Walker
- Alfredo Axtmayer
- Armand Russo, MD
- Catherine Wei, MD
- Clarice Grens
- D. Barry Boyd, MD, MS
- Daniel Boxer, MD
- Emily Kopas, APRN, OCN
- Ethan Kohn
- Francine Foss, MD
- Iris Isufi, MD
- Jose Morales-Marin
- Justine Boulanger-Parzych
- Kayla Martello
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- M. Sung Lee, MD
- Madeline Santiago
- Osarugue Otasowie
- Sara Anastasio, RN
- Scott Huntington, MD, MPH, MSc
- Stuart Seropian, MD
- Syed Ali
- Tarsheen Sethi, MD, MSc
- Vidya Kesavan
- Virginia Syombathy
- Yifei Zhang, MD
- Last Updated12/02/2025
- Study HIC#2000039878